Gene therapy has been proposed as a strategy for the treatment of intractable human diseases since the early 1990s. For the expression of a specific transgene in desired cells or tissues with the proper timing, many vectors carrying transgenes have been developed (Mátrai et al., 2010; Nayak & Herzog, 2010; Sliva & Schnierle, 2010). Retroviral, lentiviral, adenoviral, and adeno-associated viral vectors are used in various ways to achieve these goals. However, the introduced transgenes frequently become silenced in the host cells (Harbers et al., 1981; Jähner et al., 1982; Palmer et al., 1991). We searched for bioactive substances from Actinomycetes that enhance transgene expression, and found that trichostatin A (TSA), a histone deacetylase inhibitor (HDACi), enhanced several promoter activities remarkably (Y. Ma et al., 2009).
HDACis have been used as anti-cancer drugs, because they have various effects on tumor cells to arrest cell growth, induce apoptosis, inhibit metastasis, and enhance anti-tumor immunity, by regulating the expression of the relevant genes (Bolden et al., 2006; Haberland et al. 2009; X. Ma et al., 2009; Mai et al., 2005). Here, we developed effective TSA-inducible killer constructs to enhance the anti-cancer effects of TSA, by identifying the TSA-responsive element of the herpes simplex virus thymidine kinase (hsvTK) promoter, and TSA-dependently activating some cell-death-inducing genes. We determined the most relevant regions responsive to TSA, and constructed chimeric promoters with higher fold-increases and greater induced strengths with TSA, by replacing the weak TSA-responsible region (TSA2) of the CMV promoter with two or three copies of the TSA-responsible sites (TSA1) of the hsvTK promoter. In addition, the synthetic intron sequence (0.2kb) from the pRL-TK vector and the long 3’-untranslated region (1.0kb) from the pSV2-neo vector, including the SV40 late polyA site, were important for the basal expression of the transgene and the TSA-induction, respectively.
To create the TSA-inducible killer constructs, we placed the hsvTK gene for combination therapy with the prodrug Ganciclovir, and some strong death-inducing molecules (Bax, caspase8, and TRIF) under the control of the TSA-responsible chimeric promoters. They effectively killed the cells in which they were introduced, in a TSA-dependent manner. To evaluate the utility of the killer constructs for cancer gene therapy, the TSA-dependent death-inducing constructs were transferred to retroviral and adenoviral vectors.
2. TSA-induced transgene activation
2.1. Screening of actinomycetes products to enhance the transgene
Actinomycetes are the prime candidates in screens for new natural products as antitumor and antimicrobial bioactive agents, and the achievements have been well reviewed (Jensen et al., 2005; Park et al., 2008; Zheng et al., 2000). We screened the Actinomycetes products for substances that enhance the transgene promoter, using the luciferase reporter, pRL-TK vector (Promega). In the vector, the 0.75kb promoter region of hsvTK was placed upstream of the reporter Renilla luciferase gene. We found that a methanol extract of the MK616-mF5 strain increased the luciferase activity significantly, by about 41-fold, as compared to the control among 2,448 Actinomycetes products. The methanol extract from the Actinomycetes MK616-mF5 strain was purified by chromatography on a silica column and a C18 reverse-phase HPLC column, by monitoring the effects on the hsvTK-driven luciferase activities. Based on NMR and mass spectrometry analyses, we concluded that the natural product is TSA. TSA is a histone deacetylase inhibitor (HDACi), and some HDACis have recently been used in clinical trials for cancer treatment (Hoshino & Matsubara, 2010; X. Ma et al, 2009; Wagner et al., 2010). HDACi is thought to work by changing the acetylation status of core histones and thus modulating the gene expression patterns, including the genes associated with cell cycle arrest, apoptosis, and differentiation. Modifications of the N-terminal tails of core histones (the core histone is an octamer, consisting of an H3-H4 tetramer and two H2A-H2B dimers) play a crucial role in chromatin packing and gene expression. The acetylation of the core histone is illustrated in Fig. 1, although other modifications, including methylation, phosphorylation, and ubiquitination, also affect the chromatin remodeling (Gasper-Maia, et al., 2011; Mai et al., 2005). Generally, the positively-charged lysine residues in the N-terminal core histone tails, which protrude from the surface of the nucleosome, are tightly bound to the phosphate backbone of the DNA, thus maintaining the chromatin in a transcriptionally silent state (closed chromatin). The acetylation status of the core histone is controlled by the competitive activities of histone acetyl transferase (HAT) and histone deacetylase (HDAC). Acetylation neutralizes the positive charges on the core histone, and converts the chromatin to a more open state, enhancing the access of the transcriptional machinery, including RNA polymerase II, to the promoter region for gene expression. HDACis have been used as anti-cancer drugs, because they activate the expression of the TRAIL, Fas, Bid, and p53 genes to induce growth arrest and/or apoptosis of cancer cells (Bandyopadhyay et al., 2004; Nakata et al., 2004; Ogawa et al., 2004; Ruefli et al., 2001; Sonnemann et al., 2007) by inhibiting HDAC activities, and they also have anti-angiogenic and anti-metastatic effects (Bolden et al., 2006). In addition, HDACi can enhance anti-tumor immunity, either by directly affecting malignant cells to make them more attractive immune targets, or by altering immune cell activity and/or cytokine production. HDACi reportedly augments the immunogenicity of tumor cells by upregulating the expression of the major histocompatibility complex (MHC) class I and II proteins and co-stimulatory/adhesion molecules, such as CD40, CD80, CD86 and intercellular adhesion molecule-1 (ICAM-1) ((Maeda et al.,2000; Magner et al., 2000).
On the other hand, HDACis have been used to reactivate virally transduced genes and to amplify the expression of transgenes encoded by recombinant adenoviral or retroviral vectors (Chen et al., 1997; Dion et al., 1997; Khalighinejad et al., 2008; Kikuchi et al., 2007). However, the induction levels of the silenced transgenes were not sufficient to achieve satisfactory results.
To develop effective vectors exhibiting high sensitivities to TSA and sustained strong activities in the presence of TSA, we examined the responsiveness of various promoters to TSA. HeLa cells were treated with 1.0 g/ml of TSA for 24 hours, after transfections with various Renilla luciferase constructs. The TSA treatment induced remarkable transgene expression with all of the tested promoters, as shown in Fig. 2. The hsvTK promoter exhibited the highest fold-increase, and the RSV and SV40 promoters also showed relatively high fold-increases. The responses of the CMV and β-actin promoters to TSA were poor. In contrast, the CMV promoter showed the greatest strength, but the hsvTK promoter activity was weak, even in the presence of TSA.
2.2. Analyses of the TSA-responsive elements in the hsvTK and CMV promoters
To assess which region of the hsvTK promoter is responsible for the TSA stimulation, we created a series of deletion mutants within the 0.7kb promoter region of the hsvTK gene.
They were transfected into HeLa cells, and the Renilla luciferase activities were measured after a 24 hr treatment with 1.0 g/ml of TSA. The responses to TSA were reduced by the deletion of the region between 231 and 111. Therefore, this region is important for the activation of the HSV-tk promoter by TSA, and we named this region TSA1. The TSA1 region contained an octamer motif (ATTTGCAT), an NF-Y binding site (CCAAT), and a GC box. These elements are also reportedly important for the TSA-activation of other promoters (Hirose et al., 2003), consistent with our results. The TSA treatment also increased the gene expression by the CMV promoter, although the fold-increase was low. The reporter construct deletion mutant –77 almost lost its basal and TSA-induced activities. The region –281 ～ –77 is important for weak activation by TSA, and thus we named it TSA2. The weak TSA-stimulation may be related to the degenerate octamer motif (ATTTGCgT), the partial NF-Y binding site (CCAAg), and the GC box in the TSA2 region.
2.3. Development of chimeric promoters that significantly enhance transgene expression
A strong, drug-inducible promoter is urgently needed for cancer treatments, such as suicide gene therapy. The TSA1 site within the hsvTK promoter was important for the highest fold-increase. On the other hand, the CMV promoter showed the greatest induced strength, and the TSA2 site was relevant to the weak responsiveness to TSA. We succeeded in constructing chimeric promoters with a higher fold-increase and greater induced strength to TSA, by replacing the weak TSA2 site of the CMV promoter with two or three copies of the TSA1 sites of the hsvTK promoter. A schematic representation of the chimeric promoters is shown in Fig. 3a. The reporter assay revealed that the chimeric promoter HC1, containing two copies of TSA1, and the chimeric promoter HC3, containing three copies of TSA1, amplified transgene expression in response to TSA by 220.7-fold and 94.2-fold, respectively (Fig. 3b,c). The two chimeric promoters retained induced strength comparable to that of the CMV promoter.
As shown in Fig. 4, we also found that a synthetic intron (0.2kb) from the pRL-TK vector and the long 3’-untranslated region (1.0kb) from the pSV2-neo vector are important for the basal expression of the transgene and the TSA-induction, respectively. The long 3’-untranslated region lowered the basal transgene activities in the HC3-L construct, and enhanced the TSA-stimulated transgene activities in all of the constructs (CMV-L, HC1-L, and HC3-L).
2.4. TSA-dependent induction of the stably integrated transgene under the chimeric promoters to kill target cells by different mechanisms.
Considering the various escape mechanisms employed by cancer cells, we introduced the molecules that can activate different cell death-inducing mechanisms. We placed the hsvTK gene for combination therapy with the prodrug Ganciclovir, and some strong death-inducing molecules (Bax, caspase8, and TRIF) under the TSA-responsible chimeric promoters. Suicide gene therapy has been proposed as a strategy for the treatment of cancer for many years (Culver et al., 1992; Fillat et al., 2003; Mooleten et al., 1990). One of the most widely used prodrug-activating gene therapies is the thymidine kinase gene of the herpes simplex virus (hsvTK), in combination with the non-toxic prodrug Ganciclovir (GCV) (Fig. 5). The principal effect of the hsvTK/GCV system is to generate GCV triphosphate (GCV-PPP) from the non-toxic prodrug GCV, by the introduced hsvTK and several cellular kinases, including guanylate kinase. The produced GCV-PPP inhibits the mammalian DNA polymerase due to its analogy with deoxyguanosine triphosphate, and leads to cell death. The hsvTK is required for the formation of GCV-PPP; however, the GCV treatment eradicated the majority of the population, even though only 10% of the cell population was expressing hsvTK (Freeman et al., 1993). The killing of hsvTK-negative cells by adjacent hsvTK positive cells is called “bystander killing effects”, which depend mainly upon gap
junction formation, and has been established as a potentially powerful tool in cancer gene therapy (Fick et al., 1995; Denning & Pitts, 1997; Mesnil et al., 1996). To enhance the killing effects on cancer cells, the hsvTK suicide gene therapy is employed with other anti-cancer treatments, such as chemotherapy, radiotherapy, and immunotherapy. Especially, the combination therapy of hsvTK/GCV and HDAC inhibitors (HDACi) including TSA is promising for cancer therapy (Ammerpohl et al., 2004; Yamamoto et al., 2003), because HDACis have anti-cancer effects by inducing tumor cells to undergo differentiation, growth arrest and/or apoptosis, and by enhancing anti-tumor immunity, by altering gene expression through chromatin structure remodeling.
Other molecules (Bax, Caspase8, and TRIF) that induce apoptosis by activating different pathways should be beneficial for the treatment of various tumors, because each cancer employs various strategies to escape from the host immune surveillance and to gain growth advantages (Liu et al., 2011; Luo et al., 2009; Pavet et al., 2011). As shown in Fig. 6, two core pathways for inducing apoptosis exist: the extrinsic and intrinsic pathways. In the intrinsic pathway, the mitochondrion plays a central role. The mitochondrial membrane integrity is controlled by pro-apoptotic molecules (Bax, Bak, Bid, etc.) and anti-apoptotic molecules (Bcl-2, Bcl-xL, etc.). The disruption of the membrane integrity by various stimuli, including DNA-damaging agents, increases the permeability and allows the release of cytochrome
To evaluate the utility of these TSA-responsive killer constructs for cancer gene therapy, we introduced the TSA-inducible hsvTK gene constructs to a well-characterized retroviral vector. Retroviral vectors are useful tools for the long-term expression of stably integrated transgenes in target cells, although there are risks due to insertional mutagenesis and the generation of replication competent retroviruses. We used a retroviral vector, pQC (Clontech) that self-inactivates the 5' LTR to avoid promoter interference, and to reduce the risk of transactivation of genome sequences around the integration site. The hsvTK, Bax, Caspase8, and TRIF genes were placed downstream of the chimeric promoters (PHC1, and PHC3), with the PPGK-driven puromycin selection marker (Fig. 7).
To verify the activities of the constructs, we examined whether the cells in which these constructs were transiently introduced are killed by TSA treatment. The 293T cells with the PHC1- or PHC3-hsvTK gene showed TSA- and GCV-dependent cell death. The cells with the PHC1- or PHC3-driven Bax, Caspase8, or TRIF genes were also killed with 0.1~0.3 μg/ml TSA treatment. Among them, TRIF triggered the most effective cell death. To examine the effects of TSA on the stably-introduced transgene expression, we obtained stable clones to express the death-inducing molecules under the control of the HC1 and HC3 promoters, by selection with puromycin for several weeks after the retroviral infection. The 293T cells containing the PHC1-TRIF gene showed drastic cell death (apoptosis) upon a treatment with 0.1μg/ml TSA for 24h, as compared to the control 293T cells containing PCMV only (Fig. 8). The chimeric promoter PHC1 maintained the TSA-responsiveness after becoming stably-integrated into the genome DNA.
On the other hand, adenoviral or adeno-associated viral vectors are preferable to retroviral or lentiviral vectors, to avoid insertional mutagenesis by the transgene in target cells. In addition, the vectors can be inserted with the long 3’-untranslated region (UTR), to enhance the TSA-responsiveness between the inverted terminal repeats (ITRs). We constructed several adenoviral vectors containing the death-inducing genes (Bax, Caspase8, TRIF, and hsvTK) under the chimeric promoters (PHC1 and PHC3) with the long 3’ UTR sequence (Fig. 9). To monitor the transfection and infection efficiencies easily, we added the EF1α promoter-driven GFP. The recombinant adenovirus constructs were transferred from a shuttle vector (Clontech) with the specific homing endonucleases I-CeuI and PI-SceI, and showed GFP expression in the HEK293 packaging cells.
3. Specific delivery of transgenes to target cells
Another challenge is to deliver the transgene to the desired cells or tissues. Some specific delivery systems have been developed by engineering the viral envelope proteins of Lentivirus or Retrovirus, in a procedure referred to as pseudotyping, and incorporating specific antibodies and ligands (Mátrai et al., 2010). The pseudotyping with vesicular stomatitis virus glycoprotein (VSV-G) as a viral envelope protein has broadened the natural tropism of the virus to infect basically all human and murine cell types (Burns et al., 1993). Using various viral envelopes, the recombinant viruses can be introduced into different target cells, including lymphocytes and nerve cells (Colin et al., 2009; Funke et al., 2009; Miletic et al., 2004). Some viruses have two envelope proteins with distinct functions, to bind to the host receptor and to fuse with the membrane for entry (Buchholz et al., 2009). The E1 and E2 proteins of Sindbis virus (Morizono et al., 2005; Yang et al., 2006), and the H and F proteins of measles virus (Frecha et al. 2008; Funke et al., 2008) have been well characterized for the recombinant virus to infect a desired target cell (retargeting) with high transduction efficiency. The principle of retargeting using the measles H and F proteins is illustrated in Fig. 10. The natural receptor recognition of the measles H protein is ablated, and a ligand is attached that recognizes the cognate receptor on the target cell. Subsequent virus entry is mediated by the F protein pH-independently at the plasma membrane, and the transgene is delivered into the target cell. Using specific markers on target cells (specific epitope and antibody binding, or ligand and receptor binding), the transgene will be retargeted to the desired cell type. By combining this specific delivery system with a suicide gene, selective cell death of the target cells was achieved (Funke et al., 2008). Our TSA-responsible killer gene constructs can be applied to this retargeting system.
Finally, these TSA-responsible killer gene constructs can be used to eliminate the undesirable cells generated by inadvertent insertional mutagenesis in the process of gene therapy, as a biosafety measure.
Considering the various anti-cancer effects of TSA, an HDACi with the ability to reactivate silenced transgenes by altering the chromatin structure, we have developed TSA-inducible cell death systems to enhance the anti-cancer effects of TSA. The chimeric promoters PHC1 and PHC3 showed high TSA-responsiveness to express the death-inducing genes (hsvTK, Bax, Capase8, and TRIF), and the cells in which the killer constructs were introduced showed TSA-dependent cell death. Combined with specific delivery systems to target cancer cells, these killer constructs will be beneficial for cancer gene therapy. We are planning to investigate the killer efficacies of other HDACis besides TSA, because various HDACis are now available for cancer therapy. The
This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by the Global Center of Excellence Program at Nagasaki University.
Ammerpohl O. Thormeyer D. Khan Z. Appelskog I. B. Gojkovic Z. Almqvist P. M. Ekström T. J. 2004HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. 324 1November 2004), 8 14.
Bandyopadhyay D. Mishra A. Medrano E. E. 2004Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. 64 21November 2004), 7706 7710
Bolden J. E. Peart M. J. Johnstone R. W. 2006Anticancer activities of histone deacetylase inhibitors. 5 9September 2006), 769 784
Buchholz C. J. Mühlebach M. D. Cichutek K. 2009Lentiviral vectors with measles virus glycoproteins- dream team for gene transfer? 27 5May 2009), 259 265.
Burns J. C. Friedmann T. Driever W. Burrascano M. Yee J. K. 1993Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. 90 17September 1993), 8033 8037.
Chen W. Y. Bailey E. C. Mc Cune S. L. Dong J. Y. Townes T. M. 1997Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. 94 11May 1997), 5798 5803.
Colin A. Faideau M. Dufour N. Auregan G. Hassig R. Andrieu T. Brouillet E. Hantraye P. Bonvento G. Déglon N. 2009Engineered lentiviral vector targeting astrocytes in vivo. 57 6April 2009), 667 679.
Culver K. W. Ram Z. Wallbridge S. Ishii H. Oldfield E. H. Blaese R. M. 1992In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. 256 5063June 1992), 1550 1552
Denning C. Pitts J. D. 1997Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. 8 15October 1997), 1825 1835.
Dion L. D. Goldsmith K. T. Tang D. C. Engler J. A. Yoshida M. Garver R. I. Jr 1997Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. 231 2May 1997), 201 209.
Fick J. Barker F. G. 2nd Dazin P. Westphale E. M. Beyer E. C. Israel M. A. 1995The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. 92 24November 1995), 11071 11075.
Fillat C. Carrió M. Cascante A. Sangro B. 2003Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. 3 1February 2003), 13 26.
Frecha C. Costa C. Nègre D. Gauthier E. Russell S. J. Cosset F. L. Verhoeyen E. 2008Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. 112 13December 2008), 4843 4852.
Freeman S. M. Abboud C. N. Whartenby K. A. Packman C. H. Koeplin D. S. Moolten F. L. Abraham G. N. 1993The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. 53 21November 1993), 5274 5283.
Funke S. Maisner A. Mühlebach M. D. Koehl U. Grez M. Cattaneo R. Cichutek K. Buchholz C. J. 2008Targeted cell entry of lentiviral vectors. 16 8August 2008), 1427 1436.
Funke S. Schneider I. C. Glaser S. Mühlebach M. D. Moritz T. Cattaneo R. Cichutek K. Buchholz C. J. 2009Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. 16 5May 2009), 700 705.
Gaspar-Maia A. Alajem A. Meshorer E. Ramalho-Santos M. 2011Open chromatin in pluripotency and reprogramming. . 12 1January 2011), 36 47.
Haberland M. Montgomery R. L. Olson E. N. 2009The many roles of histone deacetylases in development and physiology: implications for disease and therapy. 10 1January 2009), 32 42
Harbers K. Jähner D. Jaenisch R. 1981Microinjection of cloned retroviral genomes into mouse zygotes: integration and expression in the animal. 293 5833October 1981), 540 542
Hirose T. Sowa Y. Takahashi S. Saito S. Yasuda C. Shindo N. Furuichi K. Sakai T. 2003p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. 22 49(October 2003), 7762 7773.
Hoshino I. Matsubara H. 2010Recent advances in histone deacetylase targeted cancer therapy. . 40 9September 2010), 809 815.
Jähner D. Stuhlmann H. Stewart C. L. Harbers K. Löhler J. Simon I. Jaenisch R. 1982De novo methylation and expression of retroviral genomes during mouse embryogenesis. . 298 5875August 1982), 623 628
Jensen P. R. Mincer T. J. Williams P. G. Fenical W. 2005Marine actinomycete diversity and natural product discovery. 87 1January 2005), 43 48
Kaiser W. J. Offermann M. K. 2005Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. , 174 8April 2005), 4942 4952.
Kawai T. Akira S. 2010The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. 11 5May 2010), 373 384.
Khalighinejad N. Hariri H. Behnamfar O. Yousefi A. Momeni A. 2008Adenoviral gene therapy in gastric cancer: a review. 14 2January 2008), 180 184.
Kikuchi E. Menendez S. Ozu C. Ohori M. Cordon-Cardo C. Logg C. R. Kasahara N. Bochner B. H. 2007Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. 13 15Pt. 1 (August 2007), 4511 4518.
Kitanaka C. Namiki T. Noguchi K. Mochizuki T. Kagaya S. Chi S. Hayashi A. Asai A. Tsujimoto Y. Kuchino Y. 1997Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-xL on Bax-induced caspase activation and apoptosis. 15 15October 1997), 1763 1772.
Liu J. J. Lin M. Yu J. Y. Liu B. Bao J. K. 2011Targeting apoptotic and autophagic pathways for cancer therapeutics. 300 2January 2011), 105 114.
Luo J. Solimini N. L. Elledge S. J. 2009Principles of cancer therapy: oncogene and non-oncogene addiction. 136 5March 2009), 823 837.
Ma Y. Kohno T. Igarashi M. Yasui K. Chua K. J. Matsuyama T. Hayashi H. 2009Effective transgene constructs for combination suicide gene therapy with trichostatin A. I 5 2(February 2009) 108 115, 0973-8363
Ma X. Ezzeldin H. H. Diasio R. B. 2009Histone deacetylase inhibitors: current status and overview of recent clinical trials. 69 14(October 2009), 1911 1934
Maeda T. Towatari M. Kosugi H. Saito H. 2000Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. 96 12December 2000), 3847 3856
Magner W. J. Kazim A. L. Stewart C. Romano M. A. Catalano G. Grande C. Keiser N. Santaniello F. Tomasi T. B. 2000Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. 165 12December 2000), 7017 7024.
Mai A. Massa S. Rotili D. Cerbara I. Valente S. Pezzi R. Simeoni S. Ragno R. 2005Histone deacetylation in epigenetics: an attractive target for anticancer therapy. 25 3May 2005), 261 309
Mátrai J. Chuah M. K. Vanden Driessche. T. 2010Recent advances in lentiviral vector development and applications. . 8 3March 2010), 477 490.
Mesnil M. Piccoli C. Tiraby G. Willecke K. Yamasaki H. 1996Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. 93 5March 1996), 1831 1835.
Miletic H. Fischer Y. H. Neumann H. Hans V. Stenzel W. Giroglou T. Hermann M. Deckert M. Von Laer. D. 2004Selective transduction of malignant glioma by Lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. 15 11November 2004), 1091 1100.
Moolten F. L. Wells J. M. Heyman R. A. Evans R. M. 1990Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. 1 2Summer 1990), 125 134.
Morizono K. Xie Y. Ringpis G. E. Johnson M. Nassanian H. Lee B. Wu L. Chen I. S. 2005Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. 11 3March 2005), 346 352.
Nakata S. Yoshida T. Horinaka M. Shiraishi T. Wakada M. Sakai T. 2004Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. 23 37August 2004), 6261 6271.
Nayak S. Herzog R. W. 2010Progress and prospects: immune responses to viral vectors. . 17 3March, 2010), 295 304.
Ogawa K. Yasumura S. Atarashi Y. Minemura M. Miyazaki T. Iwamoto M. Higuchi K. Watanabe A. 2004Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. 40 2February 2004), 278 284.
Palmer T. D. Rosman G. J. Osborne W. R. Miller A. D. 1991Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. . 88 4February 1991), 1330 1334.
Park S. R. Park J. W. Jung W. S. Han A. R. Ban Y. H. Kim E. J. Sohng J. K. Sim S. J. Yoon Y. J. 2008Heterologous production of epothilones B and D in Streptomyces venezuelae. 81 1November 2008), 109 117.
Pavet V. Portal M. M. Moulin J. C. Herbrecht R. Gronemeyer H. 2011Towards novel paradigms for cancer therapy. 6 1January 2011), 1 20.
Ruefli A. A. Ausserlechner M. J. Bernhard D. Sutton V. R. Tainton K. M. Kofler R. Smyth M. J. Johnstone R. W. 2001The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. 98 19September 2001), 10833 10838.
Sliva K. Schnierle B. S. 2010Selective gene silencing by viral delivery of short hairpin RNA. . 7 248September 2010).
Sonnemann J. Dreyer L. Hartwig M. Palani C. D. Hong le T. T. Klier U. Bröker B. Völker U. Beck J. F. 2007Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells. 133 11November 2007), 847 858.
Tamm I. Wang Y. Sausville E. Scudiero D. A. Vigna N. Oltersdorf T. Reed J. C. 1998IAP-family protein survivin inhibits caspase activity and apoptosis induced byFas (CD95), Bax, caspases, and anticancer drugs. 58 23December 1998), 5315 5320.
Xiang J. Chao D. T. Korsmeyer S. J. 1996BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. 93 25December 1996), 14559 14563.
Yamamoto S. Yamano T. Tanaka M. Hoon D. S. Takao S. Morishita R. Aikou T. Kaneda Y. 2003A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. 10 3March 2003), 179 186.
Yang L. Bailey L. Baltimore D. Wang P. 2006Targeting lentiviral vectors to specific cell types in vivo. 103 31August 2006), 11479 11484.
Wagner J. M. Hackanson B. Lübbert M. Jung M. 2010Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. . 1 3-4(December 2010), 117 136.
Zheng Z. Zeng W. Huang Y. Yang Z. Li J. Cai H. Su W. 2000Detection of antitumor and antimicrobial activities in marine organism associated actinomycetes isolated from the Taiwan Strait, China. 188 1July 2000), 87 91.